Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial

New treatments are needed to shorten the time required to cure tuberculosis and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new agent that might have additive activity to existing antituberculosis agents. We assessed the activity and safety of moxifloxacin in the...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Lancet (British edition) Ročník 373; číslo 9670; s. 1183 - 1189
Hlavní autori:	Conde, Marcus B, Efron, Anne, Loredo, Carla, De Souza, Gilvan R Muzy, Graça, Nadja P, Cezar, Michelle C, Ram, Malathi, Chaudhary, Mohammad A, Bishai, William R, Kritski, Afranio L, Chaisson, Richard E
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Kidlington Elsevier Ltd 04.04.2009 Elsevier Elsevier Limited
Predmet:	Adult Antitubercular Agents - adverse effects Antitubercular Agents - therapeutic use Aza Compounds - adverse effects Aza Compounds - therapeutic use Bacterial diseases Biological and medical sciences Brazil - epidemiology Double-Blind Method Drug Administration Schedule Drug Therapy, Combination Ethambutol - adverse effects Ethambutol - therapeutic use Female Fluoroquinolones General aspects Human bacterial diseases Humans Infectious diseases Internal Medicine Isoniazid - therapeutic use Kaplan-Meier Estimate Logistic Models Male Medical sciences Moxifloxacin Multivariate Analysis Mycobacterium tuberculosis Pyrazinamide - therapeutic use Quinolines - adverse effects Quinolines - therapeutic use Rifampin - therapeutic use Sputum - microbiology Time Factors Treatment Outcome Tuberculosis Tuberculosis and atypical mycobacterial infections Tuberculosis, Pulmonary - diagnosis Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology Tuberculosis, Pulmonary - mortality Brazil Brazil, Rio de Janeiro Mycobacterial infection Moxifloxacin Infection Medicine Fluoroquinolone derivatives Treatment Tuberculosis Phase II trial Bacteriosis Clinical trial Ethambutol Antituberculous agent Antibacterial agent Quinolone derivatives Comparative study
ISSN:	0140-6736, 1474-547X, 1474-547X
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!